In agreement with this notion, a recent study [38] clearly demonstrated that the diversity of pre-existing CD8+ T cell clones, likely those similar to 4-1BBlow or TRM populations identified from other studies [55,59], are critical for eliciting the favorable response within nivolumab-treated ccRCC patients. This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.